Overview

CLEAR Study: Clinical Experience Acquired With Raptiva Study

Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered Raptiva in the treatment of patients with moderate to severe psoriasis
Phase:
Phase 3
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany